Axon Enterprise, Inc $AXON Holdings Boosted by Odyssean LLC

Odyssean LLC boosted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 78.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,681 shares of the biotechnology company’s stock after purchasing an additional 1,619 shares during the period. Odyssean LLC’s holdings in Axon Enterprise were worth $2,064,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in AXON. Rockefeller Capital Management L.P. lifted its position in shares of Axon Enterprise by 53.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock worth $6,542,000 after purchasing an additional 4,002 shares in the last quarter. Legal & General Group Plc grew its position in Axon Enterprise by 1.3% during the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after purchasing an additional 5,419 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in Axon Enterprise during the fourth quarter valued at approximately $13,116,000. B. Metzler seel. Sohn & Co. AG purchased a new position in Axon Enterprise during the second quarter valued at approximately $3,854,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Axon Enterprise in the 1st quarter valued at approximately $15,067,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Stock Up 2.6%

Axon Enterprise stock opened at $613.26 on Wednesday. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $794.29. The firm’s fifty day simple moving average is $549.76 and its 200-day simple moving average is $479.31. The company has a market capitalization of $49.82 billion, a P/E ratio of 254.47, a P/E/G ratio of 9.70 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $904.39 million during the quarter, compared to analysts’ expectations of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. Axon Enterprise’s revenue for the quarter was up 35.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.12 earnings per share. Sell-side analysts forecast that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Piper Sandler increased their target price on shares of Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Barclays upped their price target on shares of Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Citizens Jmp reiterated a “market outperform” rating and set a $700.00 price objective on shares of Axon Enterprise in a report on Thursday, June 25th. TD Cowen reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, July 22nd. Finally, UBS Group boosted their target price on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.92.

Insider Activity at Axon Enterprise

In other news, CRO Cameron Brooks sold 1,242 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the transaction, the executive owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This represents a 2.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 13,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares of the company’s stock, valued at approximately $82,609,106.25. This trade represents a 7.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 76,594 shares of company stock worth $41,236,386 in the last 90 days. Insiders own 4.20% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.